Zhitong Finance App News, Heyu-B (02256) announced that the company's subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Pharmaceutical) announced that its phase II clinical study on the selective oral small molecule FGFR2/3 inhibitor lavengratinib (ABSK061) to treat achondroplasia (ACH) in children has obtained positive initial curative results. In the initial and lowest dose group (0.064 mg/kg, once daily), the annual annualized height velocity (AHV) increased by an average of +2.4 cm/ year from baseline after 27 weeks of treatment with LAVENGRATINIb for 27 weeks, and the response rate reached 100%. Lavengratinib was well tolerated overall, and no adverse events (AEs) associated with FGFR1 or FGFR2 were observed.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.